Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Completed 25 enrolled University of Miami

NaSingle-groupOpen-labelTreatment

Summary

The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).

Timeline

Start: 2009-03-25
Primary completion: 2024-06-28
Completion: 2025-05-30

Publications

Results Alderuccio JP, Saul EE, Iyer SG, Reis IM, Alencar AJ, Rosenblatt JD, Lossos IS. R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results. Am J Hematol. 2021 Jun 1;96(6):680-689. doi: 10.1002/ajh.26163. Epub 2021 Apr 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	200 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	800 mg/m2	Intravenous
Subject	Cytarabine	Small molecule	2 g	Intravenous
Subject	Doxorubicin	Other / unclassified	45 mg/m2	Intravenous
Subject	Etoposide	Small molecule	60 mg/m2	Intravenous
Subject	Ifosfamide	Small molecule	1.5 g	Intravenous
Subject	Methotrexate	Small molecule	1200 mg/m2	Intravenous
Subject	Methotrexate	Small molecule	3000 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.5 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	360 mg/m2	Intravenous
Background	G-CSF	Unknown	480 ug	Subcutaneous
Background	Leucovorin	Small molecule	10 mg/m2	Intravenous
Background	Leucovorin	Small molecule	100 mg/m2	Intravenous

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications